Coric Vlad 4

What Happened Vlad Coric, a director of Royalty Pharma plc (RPRX), received an award of 4,545 restricted stock units (RSUs) on 2026-06-05. The grant is reported as acquired at $0.00 per share (total reported value $0 at grant). This is an equity award (A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-08 (Accession 0001704317-26-000006).
• Transaction type: Award/Grant (code A).
• Shares/units granted: 4,545 RSUs; price reported $0.00; reported aggregate value $0 at grant.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The RSUs are granted under the Issuer's 2020 Independent Director Equity Incentive Plan and generally vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting in the first calendar year after the grant, subject to the plan and award agreement (see footnote F1).
• No 10b5-1 plan, tax withholding, or sale information is reported with this grant.

Context RSU grants are typical compensation for non-employee directors and represent a right to receive shares upon vesting; they are not an immediate cash purchase or sale and therefore are not a direct market-confidence signal. Upon vesting the RSUs convert to shares and may be subject to withholding or sale to cover taxes depending on the award terms.